Mathias Oelke
About Mathias Oelke
Mathias Oelke, Ph.D., is the Chief Scientific Officer and co-founder of NexImmune, known for pioneering the artificial Antigen Presenting Cell technology and having extensive expertise in cancer immunotherapy.
Mathias Oelke, Ph.D. Chief Scientific Officer
Mathias Oelke, Ph.D., serves as the Chief Scientific Officer at NexImmune. He is a scientific co-founder of the company and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. His extensive experience in cellular immunology and T cell research drives the company's innovative efforts in cancer immunotherapy. With over 20 years of research experience, Oelke has played a crucial role in advancing therapeutic methods for antigen-specific stimulation of T cells.
Mathias Oelke, Ph.D. Education and Expertise
Mathias Oelke received his Ph.D. in Biology from the University of Freiburg. His academic journey deepened his interest in the critical role of antigen-presenting cells and their application in immunotherapy. Oelke is recognized for his expertise in cellular immunology and T cell research, which has been fundamental to developing new therapeutic techniques in cancer immunotherapy.
Mathias Oelke, Ph.D. Research and Innovations
Mathias Oelke, Ph.D., is noted for his pioneering contributions to the development of artificial Antigen Presenting Cell (aAPC) technology. His research focuses on antigen-specific T cell stimulation for therapeutic use. He is also a co-inventor on more than 20 patents and patent applications describing NexImmune's proprietary aAPC technology, alongside additional pending applications in cancer immunotherapy. His work at NexImmune continues to influence the field significantly.
Mathias Oelke, Ph.D. Career Background
From 2003 to 2014, Mathias Oelke, Ph.D., was on the faculty at the Johns Hopkins University, where he further developed his expertise in cellular immunology and T cell research. His long-standing dedication to cancer immunotherapy has been a driving force throughout his career, enabling the development of innovative treatment methods. His tenure at Johns Hopkins provided a strong foundation for his subsequent achievements in biotechnology and immunotherapy.